Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 17 · above the Ichimoku cloud · RSI 55 · MACD below its signal
None of the 29 investors followed here reported a position in AEMD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AEMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 16, 2026 | Broenniman Edward GDirector | Stock Award(Grant) at price 2.29 per share. | 21.8K | $49.96K |
| Apr 16, 2026 | Rossetti AngelaDirector | Stock Award(Grant) at price 2.29 per share. | 21.8K | $49.96K |
| Apr 16, 2026 | Shah Chetan SDirector | Stock Award(Grant) at price 2.29 per share. | 21.8K | $49.96K |
| Apr 16, 2026 | Gikakis NicolasDirector | Stock Award(Grant) at price 2.29 per share. | 21.8K | $49.96K |
| Apr 22, 2025 | Broenniman Edward GDirector | Stock Award(Grant) at price 0.35 per share. | 142.9K | $50.00K |
| Apr 22, 2025 | Rossetti AngelaDirector | Stock Award(Grant) at price 0.35 per share. | 142.9K | $50.00K |
| Apr 22, 2025 | Shah Chetan SDirector | Stock Award(Grant) at price 0.36 per share. | 142.9K | $51.14K |
| Apr 22, 2025 | Gikakis NicolasDirector | Stock Award(Grant) at price 0.35 per share. | 142.9K | $50.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.7 | -19.6 | 9.0 | 1.8 | -0.9 | -62.9 | -19.5 | -37.6 | 216.5 | -14.4 | −59.7% | ||
| 2025 | -18.6 | -25.7 | -30.8 | 5.6 | -2.6 | -59.5 | -0.8 | 57.1 | -59.9 | -29.9 | -15.6 | -37.6 | −96.0% |
| 2024 | -16.9 | -5.5 | -2.3 | -17.9 | -68.1 | 13.6 | -32.0 | 11.8 | 23.7 | -17.0 | 5.1 | 109.8 | −60.7% |
| 2023 | 107.1 | -15.5 | -22.4 | 0.0 | -21.1 | 20.0 | 2.8 | -24.3 | -17.9 | -37.0 | 31.0 | 15.3 | −21.8% |
| 2022 | -20.4 | -10.8 | 10.6 | -26.7 | 25.2 | -16.4 | -10.7 | -3.0 | -40.2 | -15.5 | -14.3 | -33.3 | −84.9% |
| 2021 | -6.9 | -4.3 | -7.7 | -10.3 | -4.4 | 182.8 | -0.4 | -24.1 | 3.8 | -7.0 | -32.3 | -23.5 | −24.7% |
| 2020 | 352.1 | -37.1 | -44.3 | -7.9 | 5.0 | 38.1 | -4.4 | -26.8 | -4.9 | -0.7 | 38.8 | 32.8 | +157.3% |
| 2019 | -19.9 | -26.3 | -3.1 | -20.0 | -52.6 | 2.8 | -40.5 | 31.8 | -20.7 | 30.4 | -35.6 | -66.9 | −96.1% |
| 2018 | 32.7 | 0.7 | -21.2 | 12.6 | -6.7 | 2.4 | -3.9 | -21.1 | 21.6 | -11.9 | 21.2 | 31.7 | +46.9% |
| 2017 | 1.9 | -11.9 | -13.3 | -31.8 | -5.8 | 1.9 | -4.7 | -32.8 | 12.4 | -36.4 | 5.1 | 9.7 | −73.1% |
| 2016 | -7.4 | -23.5 | 11.4 | -9.3 | 4.5 | 12.2 | 9.3 | -17.0 | -2.9 | -5.2 | -1.7 | -10.3 | −38.1% |
| 2015 | -7.4 | -24.0 | 21.1 | -29.1 | 6.5 | -25.0 | 53.5 | -24.0 | -5.7 | 6.7 | -5.2 | -6.2 | −49.7% |
| 2014 | 5.9 | -5.6 | 11.8 | 10.5 | -9.5 | -5.3 | -22.2 | -7.1 | -7.7 | 83.3 | 136.4 | -48.1 | +58.8% |
| 2013 | 14.3 | 12.5 | 22.2 | 0.0 | -9.1 | 0.0 | 40.0 | 14.3 | 6.3 | -17.6 | 0.0 | 21.4 | +142.9% |
| 2012 | 0.0 | 140.0 | -16.7 | 10.0 | -9.1 | -10.0 | 0.0 | 0.0 | 11.1 | -20.0 | -25.0 | 16.7 | +40.0% |
| 2011 | -19.0 | -5.9 | -25.0 | -25.0 | 22.2 | -18.2 | 0.0 | -22.2 | -14.3 | 33.3 | -25.0 | -16.7 | −76.2% |
| 2010 | 16.7 | -5.7 | 15.2 | -13.2 | -3.0 | -9.4 | -6.9 | -7.4 | 4.0 | 7.7 | -14.3 | -12.5 | −30.0% |
| 2009 | 4.5 | -26.1 | 11.8 | 26.3 | 0.0 | 50.0 | -22.2 | -14.3 | 16.7 | 67.9 | -21.3 | -18.9 | +36.4% |
| 2008 | -12.0 | -25.8 | 8.2 | 3.8 | -20.0 | -6.8 | -22.0 | 21.9 | -2.6 | -15.8 | -28.1 | -4.3 | −70.7% |
| 2007 | 3.7 | 103.6 | 29.8 | -20.3 | 18.6 | -4.3 | 16.4 | -14.1 | -7.5 | -8.1 | 26.3 | 4.2 | +177.8% |
Buy / hold / sell counts
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.